CLAIMS

1. An anti-viral compound and pharmaceutically acceptable salts thereof, according to structural formula (I):

(I)



wherein:

R^1 is hydrogen, C_1-C_6 alkyl, Cl, OH, C_1-C_4 alkoxy, NH_2, or $NHZR^5$;

each of R^2 and R^3 are independently hydrogen, C_1-C_6 alkyl, methyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, Cl, I, Br, F, heterocyclyl, or R^2 and R^3 together with the carbons to which they are attached form a 5-membered ring;

R^4 is hydrogen, OH, C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_4 alkoxy, NH_2, $NHZR^5$ or $N(R^5)_2$;

each R^5 is independently C_1-C_6 alkyl, C_5-C_6 cycloalkyl, or aryl;

each of R^6, R^7, R^8 and R^9 are independently hydrogen, OH, C_1-C_6 alkyl, NH_2, $NHZR^5$, F, Cl, or Br, or R^6, R^7, R^8 and R^9 form an epoxide or a double bond;

each of Y and Y' are independently N or CH; and

Z is CO, C(O)NH or SO_2.

2. The compound according to claim 1 wherein R^1 is NH_2; R^2 is a halogen or C_1-C_4 alkyl; and R^3 and R^4 are hydrogen.

3. The compound according to claim 1 wherein R^1 is NH_2; R^2 is hydrogen or a halogen; R^3 is a halogen or C_1-C_4 alkyl; and R^4 is hydrogen.

4. The compound according to claim 1 wherein R^1 is NH_2; each of R^2 and R^3 are independently hydrogen or a halogen; and R^4 is C_1-C_4 alkyl.

5. The compound according to claim 1 wherein R^1 is NH_2; R^2 and R^3 together with the carbon atoms they are attached to form a pentene ring; and R^4 is hydrogen.

6. The compound according to claim 1 wherein R^1 is hydrogen or C_1-C_4 alkyl; each of R^2 and R^3 are independently hydrogen or a halogen; and R^4 is hydrogen.

7. The compound according to claim 1 wherein R^1 is NH2; each of R^2 and R^3 are independently hydrogen or a halogen; and R^4 is $NHZR^5$; wherein Z and R^5 are as defined in claim 1.

8. The compound according to claim 1 wherein R^6, R^7, R^8 and R^9 are hydrogen.

9. The compound according to claim 1 wherein R^6, R^8 and R^9 are hydrogen; and R^7 is OH.

10. The compound according to claim 1 wherein R^6 and R^9 are hydrogen; R^7 is C_1-C_4 alkyl; and R^8 is OH.

11. The compound according to claim 1 wherein R^6 and R^9 are hydrogen; R^7 is $NHZR^5$; and R^8 is OH; wherein Z and R^5 are as defined in claim 1.

12. The compound according to claim 1 wherein R^6 and R^9 are hydrogen; R^7 is F; and R^8 is OH.

13. The compound according to claim 1 wherein R^6 is C_1-C_4 alkyl, R^7 and R^9 are hydrogen; and R^8 is OH.

14. The compound according to claim 1 wherein said compound has structure (II):

(II)



15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14 and a pharmaceutically acceptable carrier, excipient or diluent.

16. A method of treating or preventing a viral infection, comprising administering to a subject in need thereof an anti-viral compound according to any one of claims 1 to 14 in an amount effective to treat or prevent a viral infection.

17. The method of claim 16 in which said anti-viral compound is administered orally.

18. The method of claim 16 wherein said anti-viral compound is administered systemically.

19. The method of claim 16 wherein said viral infection is caused by hepatitis B virus (HBV).

20. A method of treating or preventing a viral infection, comprising administering to a subject in need thereof a composition according to claim 15 in an amount effective to treat or prevent a viral infection.